Atlas Trials

Utilizing the Crosstalk Among Chicoric Acid, 13-Cis Retinoic Acid(Aerosolized), Minocycline and Vitamin D as a Potent Quadrate Therapy for Treating Patients With Multidrug-resistant TB and Patient With Both Multidrug-resistant TB and COVID-19

Clinical trial NCT05077813 · UNKNOWN

Trial details

NCT number
NCT05077813
Sponsor
Kafrelsheikh University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Tuberculosis
Start date
2021-12-01
Primary completion
2022-02-01
Enrollment
250

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.